Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease

Thoracic Surgery Clinics

Volumn 18, Issue 4, 2008, Pages 393-401

  Patel, Shilpen ^a   Sanborn, Rachel E ^b   Thomas Jr , Charles R ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ADD ON THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISTANT METASTASIS; DRUG CHOICE; DRUG FATALITY; DRUG TOLERABILITY; HEARING LOSS; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINUM; NEOPLASM STAGING;

EID: 53649094623     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2008.07.003     Document Type: Review

References (44)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Roth J.A., Atkinson E.N., Fossella F., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21 (1998) 1-6
3. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59 (1987) 1874-1881
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311 (1995) 899-909
5. Pritchard R.S., and Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125 (1996) 723-729
6. Marino P., Preatoni A., and Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76 (1995) 593-601
7. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
8. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
9. Sause W., Kolesar P., Taylor S.I., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
10. Morton R.F., Jett J.R., McGinnis W.L., et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 115 (1991) 681-686
11. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
12. Trovo M.G., Zanelli G.D., Minatel E., et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 24 (1992) 573-574
13. Blanke C., Ansari R., Mantravadi R., et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 13 (1995) 1425-1429
14. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
15. Curran W.J., SC, Langer C., et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non small cell lung cancer: initial report of RTOG 9410. Proceedings of the American Society of Clinical Oncology 19 (2000) 484a
16. Vokes E.E., Herndon II J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
17. Akerley W., Herndon Jr. J.E., Lyss A.P., et al. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study-CALGB 9534. Clin Lung Cancer 7 (2005) 47-53
18. Kim S., KM, Choi E., et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer: randomized phase III trial. Proc Am Soc Clin Oncol 25 (2007) 7528
19. Vokes E.E., Herndon II J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
20. Albain K.S., Crowley J.J., Turrisi III A.T., et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20 (2002) 3454-3460
21. Gandara D.R., Chansky K., Albain K.S., et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
22. Gandara D.R., CK, Albain K.S., et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group study (S9504). Clin Lung Cancer 8 (2006) 116-121
23. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26 15 (2008) 2450-2456
24. Belani C.P., Choy H., Bonomi P., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
25. Hanna N.H., NM, Ansari R., et al. Phase III trial of cisplatin plus etoposide plus concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: HOG LUN 01-24/USO-023. Proc Am Soc Clin Oncol 25 (2007) 7512
26. Lilenbaum R.C., Cashy J., Hensing T.A., et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 3 (2008) 125-129
27. Lau D.H., Crowley J.J., Gandara D.R., et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16 (1998) 3078-3081
28. Davies A.M., Chansky K., Lau D.H., et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 24 (2006) 5242-5246
29. National Cancer Institute. Available at: www.cancer.gov. Accessed September 2008.
30. Fletcher G.H. Clinical dose response curves of human malignant epithelial tumours. Br J Radiol 46 (1973) 151
31. Socinski M.A., Rosenman J.G., Halle J., et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 92 (2001) 1213-1223
32. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
33. Schild S.E., Wong W.W., Vora S.A., et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 1432-1437
34. Blackstock A.W., Ho C., Butler J., et al. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 1 (2006) 434-440
35. Blackstock A.W., SM, Bogart J., et al. Induction plus concurrent chemotherapy with high-dose (74 Gy) 3-dimensional thoracic radiotherapy in stage III non-small cell lung cancer: preliminary report of Cancer and Leukemia Group B (CALGB) 30105. Proc Am Soc Clin Oncol 24 (2006) 7042
36. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
37. Hughes S.R., LJ, Miah A., et al. Safety study of induction chemotherapy and synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer: SCRATCH (Cohort 1). Proc Am Soc Clin Oncol 25 (2007) 18032
38. Lord R.V., Brabender J., Gandara D., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
39. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
40. Bepler G., Kusmartseva I., Sharma S., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24 (2006) 4731-4737
41. Simon G.R., WC, Chiappori A.A., et al. Molecular analysis-directed individualized therapy (MADeIT) in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 25 (2007) 7502
42. Tsao M.S., ZC, Ding K., et al. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. Proc Am Soc Clin Oncol 26 (2008) 7510
43. Skrzypski M., JE, Benlloch S., et al. Validation of 5- and 3-gene expression signatures for predicting outcome in non-small cell lung cancer patients. Proc Am Soc Clin Oncol 26 (2008) 7532
44. Hsu S.D., AC, Riedel R.F., et al. Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2-8, and PAX9, to predict prognosis and guide therapeutic strategies. Proc Am Soc Clin Oncol 26 (2008) 7511